Daiichi Sankyo
Charles Hampsey is a seasoned professional in patient access and affordability, currently serving as Senior Director at Daiichi Sankyo US since September 2015, where leadership includes overseeing HUB reimbursement services and affordability programs. Previous roles include Director positions in Market Access & Reimbursement Services and Pricing & Access Strategy for Oncology, focusing on pricing strategies and asset valuation. Prior experience includes significant contributions at Bayer and Eisai US, as well as a decade at Roche Pharmaceuticals, where responsibilities ranged from public policy to oncology sales management. Charles holds a B.A. in History from the College of the Holy Cross and an M.A. in History from Stony Brook University.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.